"I’ve been impressed by the Access to Medicine Index. It presents well-balanced stakeholder views on good practices for the pharmaceutical industry and it provides clear standards against which the performance of individual companies can be judged."

Mary Robinson

Chair of the Elders, First woman President of Ireland, former UN High Commissioner for Human Rights

"Africa has been overlooked when it comes to research and development of life-saving medical commodities, including COVID-19 vaccines. Free market demand and supply principles will not work on their own without an equitable access dimension. The Access to Medicine Foundation is important for accountability - tracking how and where healthcare companies live up to their commitments; as well as encouraging them to do better – in bridging gaps in equitable access to health products and achieving universal health coverage."

Dr Githinji Gitahi

Group CEO, Amref Health Africa

"When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that."

Bill Gates

Co-chair and Trustee, Bill & Melinda Gates Foundation

"This independent Antimicrobial Resistance Benchmark is a huge step forward and shines a light on the pharmaceutical industry’s progress in tackling drug-resistant infections. It can help pave the way for a transparent learning culture where best practice is shared, progress celebrated, and gaps where further work is needed are identified.”

Dame Sally Davies

Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance and Master of Trinity College, Cambridge

"The pandemic has exposed the urgent need to expand the Access the Medicine Foundation’s proven model of engaging pharmaceutical companies to the oxygen industry. The big oxygen companies all need robust, long-term access to oxygen strategies, with performance indicators that can highlight best practices and areas where more attention is needed. The Foundation can help oxygen companies increase their impact during the pandemic, and long after the pandemic is over, by strengthening health systems to do a better job of treating tens of millions of hypoxemic patients each year.”

Leith Greenslade

Coordinator, Every Breath Counts Coalition

"As an early supporter of the Access to Medicine Foundation, I have been impressed by its growth and impact. Its credibility is based on consistent rigour and integrity, and these underpin the Foundation’s authoritative voice for urgent action to improve access to healthcare. Bringing transparency to the pharmaceutical industry, it incentivises companies to direct resources to improving healthcare in under-served markets. Since its effects are systemic, it represents good value for public money."

Michael Anderson

CEO MedAccess and former Director-General, UK Department for International Development

"The Access to Medicine Foundation has recruited hundreds of investors and trillions of dollars to champion the cause of vulnerable populations in low and middle-income countries. This will significantly influence the way in which healthcare companies do business around the world and contribute substantially to the achievement of the Sustainable Development Goals. AXA IM has actively been collaborating with and supporting the activities of the Access to Medicine Foundation for many years. We believe this is essential to positively influence the behaviors of companies we invest in and to ensure a robust and sustainable financial performance for those companies, to the ultimate benefit of our clients."

Marco Morelli

Executive Chairman, Axa Investment Managers

"There is more that we can do and are doing. This year, the Index is tougher than ever. It challenges us to think harder about how we drive innovation and enable access to our products. This is a challenge that we are ready and willing to take on. We will continue to push ourselves to go further and faster to make sure our medicines and vaccines reach more people."

Sir Andrew Witty

Former CEO, GlaxoSmithKline plc

"The Sustainable Development Goals and human rights demand accountability, which consists of monitoring, review and remedial action. By deepening monitoring, the Access to Medicine Foundation makes an indispensable contribution towards the accountability of pharmaceutical companies for the SDGs."

Paul Hunt

Professor of Law at Essex University, former UN Special Rapporteur on the right to health

“The pharmaceutical industry’s role in tackling drug-resistant infections extends beyond developing new treatments. The AMR Benchmark makes clear where companies are making commendable efforts to tackle this urgent global health problem – and it shows where further effort must now be focused. Wellcome is committed to working with industry and governments to answer the questions this report raises, by supporting new product development, and helping ensure antibiotics, old and new, are used appropriately and are available to all patients who need them.”

Jeremy Farrar

Director of the Wellcome Trust

"The Access to Medicine Index is a powerful tool for guiding and incentivising companies to do more for people living in low-and-middle-income countries, and especially in the field of NCDs. The Access to Medicine Foundation also uses its research findings to help advance the work of other partnering organisations, such as the NCD Alliance. With its unique and important role, the Foundation’s model for change encourages companies to address noted access issues."

Katie Dain

CEO NCD Alliance

"The Access to Medicine Foundation has made an important contribution in stimulating pharmaceutical companies to do more in the global fight against AIDS, TB and malaria. The AMR Benchmark is an important addition to the Foundation’s toolkit."

Peter Sands

Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria

"The Access to Medicine Foundation’s research sheds light on issues that would otherwise remain underreported when it comes to the pharma industry and access to medicine and vaccines. This research informs priority setting and policy interventions based on the identified gaps."

John-Arne Røttingen

Ambassador for Global Health, Norwegian Ministry of Foreign Affairs

“I welcome this comprehensive article on ending the burden of HIV, malaria and TB in children, and especially appreciate the strong emphasis on the crying need for children living with HIV to access the most up-to-date paediatric ARVs.”

Sister Mary Owens

Executive Director of COGRI - Nyumbani programs for children living with HIV

"The Access to Medicine Index is an effective tool for incentivising companies to develop new vaccines to fight emerging infectious diseases, including coronavirus. When companies receive credit in the Access to Medicine Index, they are encouraged to work collaboratively with CEPI and the public sector and thereby contribute to advancing society's fight against these deadly diseases."

Richard Hatchett

CEO, Coalition for Epidemic Preparedness Innovations (CEPI)

“We will not end the pandemic anywhere until we end it everywhere. The more the virus circulates, the more opportunities it has to mutate in ways that could make vaccines less effective. And the longer the pandemic drags on, the longer trade and business will be disrupted and the longer the global recovery will take. Ending the pandemic, restoring confidence and rebooting the global economy requires all of us, in the public and private sectors, pulling in the same direction. I thank the Access to Medicine Foundation for adding its voice to the chorus demanding vaccine equity.”

Dr. Tedros Adhanom Ghebreyesus

Director-General, World Health Organization

"The Access to Medicine Index is a very important project. What gets measured, gets done."

Dr. Margaret Chan

Former Director General, World Health Organization

"Responsible procurement can be a force for the public good to improve access to health technologies that are quality-assured and manufactured in an environmentally and socially responsible way. Yet, it requires credible data and rigorous research to work well. The Access to Medicine Foundation provides exactly this type of data and research, and this is why it is a long-lasting partner of United Nations Sustainable Procurement in the Health Sector (SPHS) agencies and global health financing institutions working together towards purchasing health commodities, including medicines, in a sustainable way."

Rosemary Kumwenda

Regional HIV/Health Team leader, SPHS Coordinator, UNDP

“Without the cooperation and consensus of the biggest pharmaceutical companies and all of their stakeholders, it is impossible to address today’s global health challenges. There are still so many people worldwide who cannot access the medicine they need. At the same time, I see that the will from all stakeholders to reach them is rapidly growing.”

Wim Leereveld

Founder of the Access to Medicine Foundation.

"You should be commended for taking on this difficult task in the environment of a consolidated industry with many atypical manufacturers playing important roles. We feel that the ATVI has struck a good balance, recognizing the elements that are important in access to vaccines, taking a systematic approach to comparing across manufacturers, yet recognizing and appreciating the differences in this industry."

Dr. Seth Berkley

CEO, the GAVI Alliance

“The AMR Benchmark is the first independent initiative that evaluates what pharmaceutical companies are doing to address AMR. It is clearly encouraging to see some actions to reduce the environmental pollution of antibiotics from manufacturing. However, there is still much room for improvement, particularly with regards to transparency. Incentives from outside, like the AMR Benchmark, are critically important to make sure that the pharmaceutical industry keeps moving forward.”

Joakim Larrson

Prof. Joakim Larsson, Director, Centre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Sweden

"We desperately need new antibiotics, but we can’t let the new ones go to waste. The AMR Benchmark is an important tool to spur progress on innovation, appropriate use, and clean manufacturing, providing an independent assessment following the Davos Declaration and the Industry Roadmap released in 2016."

Kevin Outterson

Professor of Law at Boston University and Executive Director of CARB-X

"The Access to Medicine Index mobilises the strength of the private sector, impacting the lives of millions of the most vulnerable people on earth. It showcases the synergy of aid, trade and investment."

Lilianne Ploumen

Former Minister for Foreign Trade and Development Cooperation

"Accountability is indispensable to the full implementation of the right to health, and the Access to Medicine Index plays an important role in promoting the responsibility of pharmaceutical corporations for a core element of the right to health – the right of everyone to access essential medicines."

Zeid Ra'ad Al Hussein

Former High Commissioner for Human Rights, United Nations

"But we at Novartis are only one piece of the puzzle. Tools like the Access to Medicine Index are useful in encouraging the pharmaceuticals industry to improve access."

Joseph Jimenez

Former CEO, Novartis AG

“The Sustainable Development Goals will only be achieved through close collaboration between the public and private sectors. Independent, data-driven benchmarks are essential to tracking and assessing progress against the world’s biggest challenges. This new Antimicrobial Resistance Benchmark will enable business, government, and civil society to work together to create a healthier, safer world against the emerging global threat posed by superbugs.”

Kathy Calvin

President and Chief Executive Officer of the United Nations Foundation.

"This year’s Index shows that the pharmaceutical industry has made progress in improving access to vital medicines for the globe’s poorest people, helping to tackle some of the world’s worst diseases. The deadly Ebola outbreak reminds us that there is still much to be done to stop the spread of diseases in developing countries."

The Rt Hon. Justine Greening

MP, Former Secretary of State for International Development,UK

"Licensing agreements between pharmaceutical companies and the Medicines Patent Pool can benefit 87-94% of people living with HIV in the developing world, and produce up to USD1.4 billion of savings for the international community. The Access to Medicine Foundation incentivises companies to engage with us and is one of our key partners to achieve impact."

Greg Perry

Assistant Director General, IFPMA

"The work of the Access to Medicine Foundation is powerful because it shows how pharmaceutical companies can and should integrate access to medicine into their business strategies. This empowers local civil society organisations to advocate for more sustainable initiatives."

Daniel Molokele

Executive Director AIDS Accountability, Pan African Civil Society Platform on Access to Medicines

"It is crucial for a CEO to have a dialogue with his/her company’s stakeholders. The Access to Medicine Index stimulates this dialogue, which is essential to bring all parties together. For this reason I highly recommend other sectors use this model as well."

Anthony Ruys

Chair Supervisory Board, STOP AIDS NOW, Former CEO of Heineken (1993-2006)

"The Access to Medicine Index has proven to provide much-needed transparency into pharmaceutical industry actions and policies. That will ultimately lead to greater access to healthcare for millions of people all over the globe."

Herman Wijffels

Former Executive Director, World Bank (2006-2008), Former Chair of Rabobank (1999-2006)

"Companies are beginning to understand that the value of corporate social responsibility programmes is not only the opportunity to do the right thing but that it's good for business as well. The Access to Medicine Index provides companies with a chance to improve performance and explore new business models while helping societies in need."

Knut Kjaer

Former CEO of RiskMetrics Group, Former CEO of Norges Bank Investment Management (NBIM)

"The AMR Benchmark brings much-needed clarity to how pharmaceutical companies approach AMR, which means investors can assess how pharmaceutical companies manage opportunities and risks created by drug-resistant infections. Such scrutiny by investors will spur pharma executives to greater activity."

Jim O'Neill

Former Chair of the UK Review on AMR

"I support the Access to Medicine Foundation's work to draw attention to the pressing issue of paediatric drug resistance and specifically pertaining to HIV, malaria and TB, along with their work to incentivise pharmaceutical companies to do more for children living in low-and-middle-income countries. Going forward, the need for new vaccines and treatments for children to address ongoing epidemics must not be forgotten.''

Professor Mike Sharland

Consultant in Paediatric Infectious Diseases at St George's University Hospitals NHS Foundation Trust

"No child should die of TB. That is why we’re working with our partners to expand the pediatric R&D pipeline. We welcome this new report for highlighting the progress to date and raising awareness of the work that still needs to be done to advance the development and delivery of new child-friendly MDR-TB treatments.”

Mel Spigelman

President and CEO, TB Alliance

"While COVID19 is dominating health systems globally, many children are still on the frontlines of the ‘big three’ infectious diseases — HIV, malaria and TB — all of which still require urgent vaccine development to save lives. The Access to Medicine Foundation provides important research and analysis on key paediatric access and drug resistance issues and incentivises companies to take action.''

Mette Gonggrijp

Former Ambassador for Women's Rights and Gender Equality, Dutch Ministry of Foreign Affairs

“Nomura Asset Management was pleased to play a role in helping to identify key opportunities in the first-of-its-kind, multi-stakeholder effort convened by the Access to Medicine Foundation and Every Breath Counts Coalition for increasing access to medical oxygen in low- and middle- income countries. The Foundation’s model of company engagement proved successful in bringing major gas companies to the table to discuss tangible solutions for this critical issue now and in the future, particularly in light of COVID-19 and the achievement of Sustainable Development Goal 3.”

Alex Rowe

Nomura Asset Management

“The pharmaceutical industry’s role in tackling drug-resistant infections extends beyond developing new treatments. The AMR Benchmark makes clear where companies are making commendable efforts to tackle this urgent global health problem – and it shows where further effort must now be focused. Wellcome is committed to working with industry and governments to answer the questions this report raises, by supporting new product development, and helping ensure antibiotics, old and new, are used appropriately and are available to all patients who need them.”

Sir Jeremy Farrar

Director, the Wellcome Trust

“Full access to sexual and reproductive health and rights is the bedrock of gender equality. Pharmaceutical companies can help to pave the way forward, and the Access to Medicine Foundation plays a central role in encouraging them to fill treatment gaps and increase access to medicine for girls and women across the world.”

Katja Iversen

President & CEO, Women Deliver

"This [Access to Vaccines] Index can help to identify product gaps as well as challenges on affordability, pricing policy transparency, research and development, and supply, to drive positive change and reach more people with life-saving vaccines.”

Seth Berkley

CEO, Gavi, the Vaccine Alliance

“The Access to Medicine Index shows that investor engagement works. We hope that more investors will join the initiative and contribute to us being able to both save lives and create conditions for fair growth.”

Carina Silberg

Head of Governance and Sustainability, Alecta

“The Access to Medicines Index is a critical component of our research into pharmaceutical companies, providing insight into unmet global health needs and emerging markets trends, while helping us evaluate the relative role of large public issuers in advancing healthcare access in underserved communities.”

Carole Laible

CEO, Domini Impact Investments

"The survival rate for childhood cancers is approximately 80% in high- income countries while, according to the WHO, less than 30% of children with cancer survive in low and middle-income countries (LMICs). Addressing this inequality is a social obligation. UICC welcomes this report and calls for all stakeholders to come together to improve access for new and existing medicines, and to simultaneously address other aspects of comprehensive treatment and care, like access to diagnostics, capacity building of the health work force and building a strong referral system."

Prof. Anil D’Cruz

President, The Union for International Cancer Control (UICC)

''ELMA greatly values the Access to Medicine Foundation and their work to make children and infants, and particularly those living in Sub-Saharan Africa, a bigger priority. Their new report outlines the issues impeding access, highlights potentially game-changing innovations for kids, and offers concrete solutions for a variety of stakeholders to consider for ramping up access. Together, we can ensure that investments in health innovations reach children urgently in need, including for neglected tropical diseases and HIV to move forward towards an AIDS-free generation.''

Tom McPartland

ELMA Philanthropies

Back to top |